<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04349176</url>
  </required_header>
  <id_info>
    <org_study_id>NMCSD.2016.0039</org_study_id>
    <nct_id>NCT04349176</nct_id>
  </id_info>
  <brief_title>Onabotulinum Dose Comparison in Chronic Migraine Superior to 100 Units?</brief_title>
  <official_title>OnabotulinumtoxinA for Chronic Headaches: Is 155 Units Superior to 100 Units?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United States Naval Medical Center, San Diego</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United States Naval Medical Center, San Diego</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will enroll patients through the Neurology Department at Naval Medical Center San
      Diego (NMCSD). Eligible participants will meet criteria for chronic migraine, but will not be
      excluded based on the presence of significant comorbidities. Participants with comorbidities
      and medication regimens commonly exhibited within real-world DOD medical settings will not be
      excluded, such as pain disorders, psychiatric illness, medication overuse, and those who have
      used prophylactic medication during the baseline period.

      This will comprise &quot;Group A&quot;. A carefully screened group will comprise &quot;Group B&quot; and meet
      exclusion criteria designed to approximate that of the PREEMPT2 trial. Within each group,
      half of the patients (155U Arm) will be randomly selected to receive the standard 155U over
      31 fixed sites every 12 weeks while the other half (100U Arm) will receive 100U over 19 fixed
      sites every 12 weeks. Minimum sample size for the entire cohort is 132 participants (maximum
      n = 180), with a minimum of 66 participants per comparison.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean change in frequency of headache days for the baseline period compared to the 28-day period ending with week 24</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>frequency of migraine days</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with severe (&gt;=60) HIT-6 score</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute headache pain medication intakes</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean change in total HIT-6</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Chronic Migraine, Headache</condition>
  <arm_group>
    <arm_group_label>Group A 100U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A 155U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B 100U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B 155</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose</intervention_name>
    <description>Randomized to either 100U or 155U</description>
    <arm_group_label>Group A 100U</arm_group_label>
    <arm_group_label>Group A 155U</arm_group_label>
    <arm_group_label>Group B 100U</arm_group_label>
    <arm_group_label>Group B 155</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Chronic migraine headache - Diagnostic criteria:

        A. Headache (tension-type-like and/or migraine-like) on 15 days per month for &gt;3 months2
        and fulfilling criteria B and C B. Occurring in a patient who has had at least five attacks
        fulfilling criteria B-D for 1.1 Migraine without aura and/or criteria B and C for 1.2
        Migraine with aura

        C. On 8 days per month for &gt;3 months, fulfilling any of the following 3 :

          1. criteria C and D for 1.1 Migraine without aura

          2. criteria B and C for 1.2 Migraine with aura

          3. believed by the patient to be migraine at onset and relieved by a triptan or ergot
             derivative D. Not better accounted for by another ICHD-3 diagnosis. -

        Exclusion Criteria:

        Previous exposure at any time to any botulinum toxin serotype Pregnancy, breastfeeding or
        plans to become pregnant within 6 months Age &lt;18 years Failure to complete at least 20 days
        of headache diary in the 28 day baseline period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sarah Hodges, DO</last_name>
    <phone>6195327472</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Naval Medical Center San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Hodges, DO</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>United States Naval Medical Center, San Diego</investigator_affiliation>
    <investigator_full_name>Sarah Hodges, DO</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

